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ABSTRACT        
 
Objective. Atherosclerosis and restenosis are multifactorial diseases associated with abnormal vascular 
smooth muscle cell (VSMC) proliferation. Nuclear factor-Y (NF-Y) plays a major role in 
transcriptional activation of CYCLIN B1 (CCNB1), a key positive regulator of cell proliferation and 
neointimal thickening. Here, we investigated the role of NF-Y in occlusive vascular disease. 
 
Approach/Results.  We performed molecular and expression studies in cultured cells, animal models 
and human tissues. We find up-regulation of NF-Y and cyclin B1 expression in proliferative regions of 
murine atherosclerotic plaques and mechanically-induced lesions, which correlates with higher binding 
of NF-Y to target sequences in the CCNB1 promoter. NF-YA expression in neointimal lesions is 
detected in VSMCs, macrophages and endothelial cells. Platelet-derived growth factor-BB (PDGF-
BB), a main inductor of VSMC growth and neointima development, induces in rat and human VSMCs 
the recruitment of NF-Y to the CCNB1 promoter and augments both CCNB1 mRNA expression and 
cell proliferation through extracellular signal-regulated kinase 1/2 (Erk1/2) and Akt activation. 
Moreover, adenovirus-mediated overexpression of a NF-YA dominant-negative mutant inhibits PDGF-
BB-induced CCNB1 expression and VSMC proliferation in vitro and neointimal lesion formation in a 
mouse model of femoral artery injury. We also detect NF-Y expression and DNA-binding activity in 
human neointimal lesions. 
 
Conclusions. Our results identify NF-Y is a key downstream effector of the PDGF-BB-dependent 
mitogenic pathway that is activated in experimental and human vasculoproliferative diseases. They also 
identify NF-Y inhibition as a novel and attractive strategy for the local treatment of neointimal 











Abnormal cell proliferation is a component of the chronic inflammatory response that promotes 
atherosclerosis and restenosis post-angioplasty.1, 2 Studies with genetically-modified mice have shown 
that ablation of the growth suppressors p53, p27, and pRb aggravates atherosclerosis in 
hypercholesterolemic mice.1, 3 Gene therapy strategies that inhibit positive cell cycle regulators (e.g., 
cyclin-dependent kinases and cyclins) or upregulate growth suppressors (e.g., p16, p21, p27, p53, p57, 
RB2/p130) have also proved efficient at reducing neointimal thickening in animal models of 
atherosclerosis and restenosis.1, 3 Importantly, the incidence of clinical restenosis is significantly 
diminished by the use of stents that locally deliver antiproliferative drugs.2  
Cell proliferation requires the sequential activation of cyclin-dependent kinase/cyclin 
complexes.4 Expression of cyclin B1 (encoded by the CCNB1 gene), which is essential for progression 
through mitosis and for mouse embryonic development,5 is induced in the rat carotid artery model of 
balloon angioplasty.6 Moreover, inhibition of CCNB1 by local delivery of antisense oligonucleotides 
reduces neointima formation in this animal model.7 Identification of the mechanisms that control 
CCNB1 expression in the vasculature may therefore provide insight into the pathogenesis of 
atherosclerotic disease. The CCNB1 promoter contains two CCAAT sites located at positions -17/-13 
and +16/+20 relative to the transcription start site that are essential for CCNB1 transcription during the 
G2/M cell cycle transition.8, 9 These CCAAT motifs bind nuclear factor -Y (NF-Y, also called CBF: 
CCAAT-binding factor), a ubiquitously expressed trimeric transcription factor formed from NF-YA, 
NF-YB and NF-YC subunits.10 CCAAT boxes are present in approximately 25% of eukaryotic genes, 
and cell culture experiments demonstrate that NF-Y is required for the proliferation of fibroblasts and 
tumor cells.9-13 However, the expression and function of NF-Y in the context of vascular 
pathophysiology has not been reported. Here, we hypothesized that NF-Y activation is important for 
the proliferative response associated with atherosclerosis and restenosis. To test this hypothesis, we 
performed expression and molecular studies using cultures of rat and human vascular smooth muscle 
cells (VSMCs), animal models (rat carotid artery balloon angioplasty and apolipoprotein E-null mouse: 
apoE-KO) and human atherosclerotic and restenotic tissue. We also analyzed the consequences of 
inactivating NF-Y on VSMC proliferation in vitro and vascular lesion formation in a mouse model of 







NF-Y activation in mechanically-injured rat arteries. We investigated NF-Y expression and activity 
in animal models of vasculoproliferative disease. First, we analyzed by immunohistochemistry the 
expression of NF-YA in balloon-injured rat carotid artery. We also examined the expression of cyclin 
B1 and PCNA, two positive regulators of cell proliferation that are induced in this animal model and 
contribute to neointimal thickening.6, 7, 14, 15 We found faint expression of these proteins in uninjured 
vessels (n=4), which was markedly increased in the lesions at early stages (7-12 days post-angioplasty, 
n=5) and advanced stages (14-18 days post-angioplasty, n=4) of neointimal thickening (Fig.1A). 
Quantification revealed the following percentages of immunoreactive area in early and advanced 
neointimal lesions: 33±7% and 29±7%  for NF-YA, 28±5%  and 30±10%  for cyclin B1, and 37±10% 
and 22±7% for PCNA. Double immunofluorescence staining showed NF-YA/cyclin B1colocalization 
in neointimal lesions (Fig.1B) and NF-YA expression in neointimal VSMCs (Fig.1C) and endothelial 
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cells (Supplemental Fig. IA).  Moreover, double smooth muscle α-actin (SMA)/NF-YA and 
SMA/cyclin B1 immunohistochemical analysis of consecutive sections revealed abundant expression 
of both NF-YA and cyclin B1 in neointimal SMA-positive VSMCs, which are the main component of 
mechanically-induced lesions in this animal model (Supplemental Fig. II). 
To investigate the potential contribution of NF-Y to cyclin B1 upregulation after balloon-
angioplasty, we performed EMSA with a radiolabeled probe spanning the CCAAT-box located at -17/-
13 in the CCNB1 promoter.8 Uninjured rat carotid arteries exhibited no detectable NF-Y DNA-binding 
activity (Fig.1D, ln.2 and 4), but binding progressively increased at 3 (ln.3) and 7 (ln.5) days post-
angioplasty. The retarded NF-Y probe was efficiently competed out by unlabeled NF-Y consensus 
oligonucleotide (ln.6), but not by NF-Y mutant (ln.7). The specificity of the nucleoprotein complex 
was further confirmed by the supershift produced by preincubation of lysates with anti-NF-YA (ln.8), 
but not with isotype-matched control antibody (ln.9). Mechanically-induced neointimal lesions in this 
animal model thus display abundant NF-YA expression and DNA-binding activity associated with the 
CCAAT motif at -17/-13 in the CCNB1 promoter. 
 
NF-Y is a downstream effector of the platelet-derived growth factor-BB (PDGF-BB)-extracellular 
signal-regulated kinase 1/2 (Erk1/2)-Akt mitogenic pathway in VSMCs. Since PDGF-BB potently 
induces VSMC proliferation in vitro and is essential for neointimal hyperplasia in animal models of 
balloon angioplasty,16 we sought to investigate whether NF-Y is a downstream effector of this 
cytokine. We first performed experiments with rat aortic E19P cells stimulated with PDGF-BB after 
starvation. qPCR and Chip assays showed that PDGF-BB significantly induced NF-YA mRNA 
expression and in vivo recruitment of NF-Y to the CCNB1 promoter, reaching a maximum after 8 
hours (Fig.2A). This was reflected in the expression of CCNB1 mRNA and S-phase entry at 16 hours, 
detected by qPCR and 5’-bromo-2’-deoxyuridine (BrdU) incorporation, respectively. These three 
parameters returned to basal levels 32 hours after stimulation (Fig.2A), and were all significantly 
blunted by pretreatment of E19P cells with either U0126 (inhibitor of Erk1/2 activation) or the Akt 
inhibitor X, but not the p38 inhibitor SB203580 (Fig.2B). U0126 and Akt inhibitor X similarly 
reduced PDGF-BB-dependent NF-Y binding to the CCNB1 promoter, CCNB1 mRNA expression and 
cell proliferation in human VSMCs (Fig.2C). 
 
Effects of NF-Y inactivation on primary VSMCs and endothelial cells. We next investigated whether 
NF-Y activity is involved in CCNB1 expression and proliferation in primary rat and human VSMCs. 
Cells were infected with either AdGFP, which encodes GFP, or Ad(GFP+NF-YAdn), which gives rise 
to a bicistronic mRNA encoding both GFP and a dominant-negative mutant NF-YA13m29 that 
inhibits NF-Y activity.17 Ad(GFP+NF-YAdn)-infected rat VSMCs overexpressed NF-YA13m29 
(Fig.3A) and exhibited reduced NF-Y DNA-binding activity (Fig.3B, ln.4 versus 2 and 3). Moreover, 
compared with control AdGFP, Ad(GFP+NF-YAdn) impaired FBS-dependent upregulation of 
CCNB1mRNA and BrdU incorporation in rat VSMCs (Fig.3C). Infection of human VSMCs with 
Ad(GFP+NF-YAdn) also reduced PDGF-BB-dependent CCNB1 mRNA expression and proliferation 
(Fig.3D). We also found a slight but significant increase in apoptosis in Ad(GFP+NF-YAdn)-infected 
rat VSMCs compared with Ad-GFP-infected controls (Supplemental Fig. IIIA). In marked contrast, 
NF-YA inactivation did not affect proliferation and apoptosis in primary mouse aortic endothelial cells 






Inhibition of NF-Y activity reduces neointimal thickening induced by arterial denudation. To assess 
the effects of inhibiting NF-Y on neointimal thickening in vivo, we performed gene therapy studies 
using a mouse model of femoral artery wire-injury. Immediately after injury, Ad(GFP+NF-YAdn) or 
control AdGFP was infused intraluminally and arteries were exposed to the virus for 20 minutes. 
Arteries were removed 9 days after denudation. Effective gene delivery was demonstrated by the 
presence of GFP-immunoreactive cells in arteries infected with either viral vector, but not in control 
(uninfected, uninjured) vessels (Fig.4A). To examine the effect of NF-YAdn expression on DNA-
binding activity, we performed EMSAs with arterial lysates and a probe containing the NF-Y binding 
site at -17/-13 in the CCNB1 promoter. Control experiments using lysates from AdGFP-infected 
arteries revealed a retarded nucleoprotein complex that was abrogated with either unlabeled NF-Y 
consensus oligonucleotide or anti-NF-YA antibody, but not with NF-Y mutant oligonucleotide or anti-
CREBII (Fig.4B). In agreement with the results in the rat carotid artery angioplasty model (Fig.1D), 
NF-Y DNA-binding activity was undetectable in uninjured mouse femoral arteries and was markedly 
upregulated in injured vessels (Fig.4C, ln.2 versus 3). Importantly, ectopic expression of NF-YAdn 
significantly reduced injury-induced DNA-binding activity (Fig.4C, ln.3 versus 4) and inhibited 
neointimal thickening (47% reduction in intima-to-media ratio, p=0.002) without significantly affecting 
medial area (Fig.4D).  
 
NF-Y activation in mouse atherosclerotic lesions. We also studied the role of NF-Y in native 
atherosclerosis by performing immunohistochemical analysis in atherosclerosis-prone apoE-KO mice 
and wild-type controls (Fig.5A). Expression of NF-YA, cyclin B1 and the proliferation marker Ki67 
was faint in cross-sections of non-atherosclerotic aortas from wild-type and apoE-KO mice fed control 
diet. In marked contrast, atherosclerotic lesions of fat-fed apoE-KO mice contained areas that were 
immunoreactive for these proteins (NF-YA: 30±4%; cyclin B1: 25±2%; Ki67: 9±2%), which were also 
expressed in spontaneously-formed lesions in older apoE-KO mice fed control chow (not shown). 
Double immunofluorescence experiments in aorta from fat-fed apoE-KO mice revealed abundant NF-
YA expression in neointimal macrophages and VSMCs, which are the predominant cells in the 
atheroma (Fig.5B). Moreover, these cells express cyclin B1, as revealed by double 
immunohistochemical analysis (Supplemental Fig. IV). We also find NF-YA expression in 
endothelial cells lining atherosclerotic lesions (Supplemental Fig. IC).  
We next performed EMSA using the NF-Y binding site at -17/-13 in the CCNB1 promoter, 
which revealed increased NF-Y DNA-binding activity in the atherosclerotic aortic arch and thoracic 
aorta of apoE-KO mice (Fig.5C, ln.3 and 5) compared with non-atherosclerotic tissue from wild-type 
controls (Fig.5C, ln.2 and 4). Specificity of the retarded nucleoprotein complexes was demonstrated 
by competition and supershift assays (Fig.5C, ln.6-10). 
 
 
NF-Y activation in human restenotic and atherosclerotic lesions. To address the clinical relevance of 
our findings, we carried out pilot immunohistochemistry studies to analyze NF-YA expression in 
human restenotic and atherosclerotic vessels. In human restenotic coronary artery tissue obtained by 
percutaneous directional atherectomy, NF-YA was detected in 9 out of 10 specimens analyzed, with 
varying degrees of expression among the different patients (Fig.6A). The analysis of consecutive 
sections of human restenotic tissue revealed regions with abundant NF-YA and cyclin B1 expression 
(Fig.6B).  
We also detected NF-YA in 7 out of 8 human atherosclerotic coronary artery specimens 
(Fig.6C). The analysis of consecutive sections showed regions with abundant NF-YA and cyclin B1 
expression (Fig.6D), and double immunofluorescence studies revealed NF-YA expression in 
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neointimal VSMCs and endothelial cells lining the lesions (Supplemental Fig. V). As shown in 
Fig.6E, human atherosclerotic coronary arteries (ln. 12-16) also exhibited increased NF-Y DNA-
binding activity compared with control internal mammary arteries (ln. 2-6) and coronary arteries (ln. 7-
11) (7.6±1.3 fold increase, p<0.001). Specificity of the retarded nucleoprotein complexes was 









Cyclin B1 is essential for cell cycle progression and its genetic disruption in the mouse causes 
embryonic lethality.5 Under normal conditions, cyclin B1 expression is tightly regulated to ensure that 
it accumulates appreciably only during the G2/M cell cycle transition.9 Aberrantly high levels of cyclin 
B1 throughout the cell cycle as a result of deregulated gene transcription is associated with excessive 
cell proliferation in several human cancers.18 Moreover, expression of cyclin B1 is induced in balloon-
injured rat carotid artery,6 and local delivery of antisense oligonucleotides against CCNB1 inhibits 
neointima formation in a rat carotid artery model of balloon angioplasty.7 While these results highlight 
the role of CCNB1 in promoting mechanically-induced neointimal thickening, the mechanisms that 
regulate its expression in vascular cells remain elusive. In the present study, we hypothesized that 
induction of the heterotrimeric transcription factor NF-Y, acting through increasing CCNB1 expression, 
is important for neointimal thickening. We focused on NF-YA because NF-Y activity is mainly 
controlled through changes in NF-YA protein expression and post-translational modifications.10 By 
combining cell culture experiments and studies with animal models and human specimens, we provide 
evidence that NF-Y plays an important role in inducing cyclin B1 expression and VSMC proliferation 
in atherosclerotic and restenotic lesions (Fig.7). We have shown that balloon angioplasty in the rat 
carotid artery causes a temporally and spatially coordinated expression of NF-YA and cyclin B1 in 
neointimal lesions with proliferative activity. Using this model and a mouse model of arterial wire 
injury, we also find a marked upregulation of NF-Y DNA-binding activity in the damaged vessel wall. 
Likewise, expression of NF-YA, cyclin B1 and the proliferation marker Ki67 is upregulated in 
atheromata of apoE-KO mice, and this is accompanied by a marked increase in NF-Y DNA-binding 
activity compared with non-atherosclerotic tissue. NF-Y-dependent induction of cyclin B1 expression 
may also contribute to neointimal cell proliferation in patients, since our pilot studies revealed 
expression of both proteins in human atherosclerotic and restenotic tissue, as well as increased NF-Y 
DNA binding to its target sequence in the CCNB1 promoter in atherosclerotic coronary arteries 
compared with control vessels. Future studies are thus warranted to further investigate the expression 
and activity of NF-Y in a larger set of occlusive vascular lesions.  
Our studies revealed expression of NF-YA in neointimal VSMCs and macrophages and in 
endothelial cells lining neointimal lesions. Interestingly, we find that adenovirus-mediated NF-Y 
inhibition does not affect endothelial cell proliferation and apoptosis in vitro. It will be important to 
ascertain whether NF-Y exerts cell cycle- and apoptosis-independent actions in vascular endothelial 
cells and/or neointimal macrophages. For example, given that NF-Y regulates myeloid differentiation,19 
studies are warranted to investigate its role in macrophage inflammatory response, including cytokine 
production, phagocytic activity and lipoprotein uptake. Future studies should also address whether NF-
Y expression/activity in vascular cells and macrophages is regulated by lipid-modulating and anti-
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inflammatory strategies recently developed to treat atherosclerosis,20 and to ascertain whether these 
new therapies may cooperate with anti-NF-Y approaches. 
Consistent with previous studies in fibroblasts and tumor cells that demonstrated reduced 
CCNB1 expression and cell proliferation upon inhibition of NF-Y DNA-binding activity,11-13, 21 we find 
that NF-Y inhibition in cultures of VSMCs reduces mitogen-induced CCNB1 expression and cell 
proliferation. The in vivo relevance of these results is further highlighted by the observation that 
intraluminal delivery of adenovirus encoding the dominant-negative NF-YA mutant inhibits NF-Y 
DNA-binding activity and neointima development in a mouse model of arterial injury. Cell 
proliferation occurs mainly at early stages of vascular remodeling induced by mechanical injury.3 We 
found no differences in neointimal Ki67 immunoreactivity in arteries infected with Ad(GFP+NF-
YAdn) at the time point analyzed for lesion quantification (Supplemental Fig. IIIB), which 
corresponds to an advanced stage of disease progression. These results suggest that NF-Y inhibits 
VSMC proliferation during the first days after vessel denudation. Given that apoptotic cell death also 
occurs in mechanically-injured arteries, we also analized the effect of NF-YA inactivation on 
apoptosis. Whilst we found a modest increase in apoptosis of primary VSMCs infected with 
Ad(GFP+NF-YAdn), NF-YA inactivation did not affect apoptosis in mouse femoral neointimal lesions 
and in primary endothelial cell cultures. 
Studies in animal models of atherosclerosis and arterial denudation have conclusively 
demonstrated that neointimal thickening is significantly dependent upon PDGF signaling, and both 
PDGF-BB and its receptor PDGFR-β are expressed in atherosclerotic and restenotic lesions in 
experimental animals and humans.16 It is now recognized that the Erk1/2 and Akt signaling cascades 
are downstream effectors of PDGF in VSMCs22-24 that stimulate neointimal thickening after vascular 
injury,25, 26 The results of our qPCR and ChIP studies demonstrate that PDGF-BB induces NF-Y 
expression and its recruitment to the endogenous CCNB1 promoter in rat and human VSMCs, and this 
is followed by increased CCNB1 mRNA expression and cell proliferation. These responses to PDGF-
BB are impaired upon treatment with pharmacological inhibitors of either Erk1/2 or Akt or by NF-YA 
dominant-negative mutant overexpression. Collectively, our results identify NF-Y as an important 
downstream mediator in the PDGF-BB-Erk1/2-Akt-dependent signaling cascade that contributes to 
neointimal thickening through the induction of CCNB1 expression and VSMC proliferation (Fig.7). It 
is therefore possible that inhibiting NF-Y would offer a more specific and safer strategy than targeting 
its upstream effectors Akt and Erk1/2, which control multiple physiological processes that are essential 
for the maintenance of cellular and organismal homeostasis (e.g., differentiation, motility, apoptosis, 
autophagy, angiogenesis, metabolism, and protein synthesis).27, 28 In this regard, the 
pyrrolobenzodiazepine-polyamide conjugate GWL-78 has been shown to displace NF-Y from several 
CCAAT motifs within promoters of cell cycle genes, and to block fibroblast proliferation.13 Preclinical 
studies in large animal models are thus warranted to explore the efficacy of GWL-78 at preventing 
neointimal thickening. 
In summary, our results show that the transcription factor NF-Y is induced in experimental and 
human atherosclerosis and restenosis. We also find that adenovirus-mediated inactivation of NF-Y 
attenuates PDGF-BB-induced VSMC proliferation in vitro and the development of neointimal lesions 
in a mouse model of vascular injury. We therefore propose that NF-Y is an attractive novel target for 
intervention in atherosclerosis and restenosis as well as other vascular-remodeling diseases that display 
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Excessive vascular smooth muscle cells (VSMC) proliferation contributes to neointima formation 
during atherosclerosis and restenosis post-angioplasty. Here, using rodent models and human 
specimens, we show that the transcription factor NF-Y is activated in neointimal lesions and is a key 
downstream mediator of the PDGF-BB-Erk1/2-Akt signaling cascade that contributes to VSMC 
proliferation. Adenovirus-mediated overexpression of a NF-YA dominant-negative mutant inhibits 
VSMC but not endothelial cell proliferation in vitro, and attenuates neointimal thickening in a mouse 
model of wire injury. Targeting NF-Y might offer a more specific and safer strategy for limiting in-
stent restenosis than inhibition of its upstream effectors, which control multiple homeostatic processes. 
A candidate drug is the anti-NF-Y compound GWL-78, which inhibits cell-cycle gene expression and 
proliferation. Preclinical studies are thus warranted to assess the efficacy of anti-NF-Y strategies in 
vascular-remodeling disorders involving VSMC hyperplasia, such as atherosclerosis, restenosis, 





Fig.1. Upregulation of NF-YA and cyclin B1 expression and NF-Y DNA-binding activity in 
balloon-injured rat carotid artery. (A) Representative examples of immunohistochemical analysis in 
early (10 d) and advanced (18 d) stages of neointimal thickening. Black and white arrowheads: internal 
and external elastic lamina, respectively. Bar: 50 µm. (B) Double confocal immunofluorescence 
microscopy of neointimal lesion. Bar: 10 µm. (C) Confocal immunofluorescence microscopy of 
neointimal lesion showing smooth muscle α-actin (SMA), NF-YA and nuclei (DAPI). Arrowheads: 
NF-YA/SMA-positive cells. Bar: 20 µm. (D) EMSA with arterial lysates and a radiolabeled NF-Y 
binding site containing the CCAAT-box at -17/-13 in the human CCNB1 promoter (NF-Ycons). 
Competition assays (ln.6, 7) were carried out with unlabeled NF-Ycons or mutated (NF-Ymut) 
oligonucleotide. For supershift assays (ln.8, 9), extracts were preincubated with antibodies. 
 
Fig.2. PDGF-BB induces NF-Y binding to the CCNB1 promoter, cyclin B1 expression and VSMC 
proliferation via Erk1/2 and Akt. Serum-starved rat E19P cells (A, B) and primary human VSMCs 
(C) stimulated with PDGF-BB to perform Chip, qPCR, and BrdU incorporation assays (n=3-4). 
Results are expressed relative to unstimulated cells (=1). When indicated, cells were treated with 
SB203580 (p38MAPK inhibitor), U0126 (Erk1/2 inhibitor) or Akt inhibitor X. PDGF-BB was added 
and cells were collected after 8 hours (Chip) and 16 hours (qPCR, BrdU incorporation). (C) Cells were 
cultured with or without U0126 and Akt inhibitor X. PDGF-BB was added and cells were collected at 
12 hours (Chip) and 24 hours (qPCR, BrdU incorporation).*: p<0.05, **: p<0.01, ***: p<0.001, versus 
vehicle.  
 
Fig.3. NF-Y inactivation in VSMCs reduces CCNB1 expression and cell proliferation. Primary rat 
(A, B, C) and human (D) VSMCs were infected with AdGFP (encoding GFP) or Ad(GFP+NF-YAdn) 
(which gives rise to a bicistronic mRNA encoding both GFP and NF-YA13m29 dominant-negative 
mutant). (A) Western blot of nuclear and cytoplasmic fractions. Nuclear lamin A/C was analyzed to 
control for fraction purity. (B) EMSA using nuclear extracts and NF-Ycons probe. Ln.5, 6: 
competition with 50-fold molar excess of unlabeled NF-Ycons or NF-Ymut oligonucleotide. (C) 
Serum-starved cells stimulated with 20% FBS. CCNB1 mRNA (qPCR) and proliferation (BrdU 
incorporation) analyzed after 16 and 24 hours of stimulation, respectively. (D) Serum-starved cells 
stimulated with PDGF-BB. CCNB1 mRNA and proliferation analyzed after 24 hours of stimulation. 
Results of qPCR are expressed relative to unstimulated cells (=1, discontinuous line). The percentage 
of BrdU-immunoreactive cells was determined in GFP-positive cells and the results are expressed 
relative to AdGFP (=1).  
 
Fig.4. NF-Y inhibition by local adenoviral transduction of NF-YAdn attenuates neointimal 
thickening in a mouse femoral artery injury model. All studies were performed with tissue 
extracted 9 days after wire injury. (A) Representative immunohistochemistry of GFP expression. The 
tunica media is delimited by discontinuous lines (red: internal elastic lamina; black: external elastic 
lamina).  No Ab: negative control lacking primary antibody. All images are at the same magnification 
(Bar: 20 µm). (B) EMSA with NF-Ycons probe and lysates from AdGFP-infected arteries (pool of 14 
arteries). (C) EMSAs using NF-Ycons probe and lysates from control (uninjured, uninfected) and 
injured arteries infected with either AdGFP or Ad(GFP+NF-YAdn) (pools of 4, 14 and 12 arteries, 
respectively). Only retarded nucleoprotein complexes are shown in representative autoradiographs. 
Graph: quantification of retarded complex intensities averaged from 7 independent EMSAs (relative to 
uninjured=1). *: p<0.05, **: p<0.001, versus uninjured. (D) Quantification of medial and intimal area, 
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intima-to-media, and stenosis. Representative photomicrographs of hematoxylin-eosin and Masson’s 
trichrome staining. Bar: 100 µm.  
 
Fig.5. Upregulation of NF-YA and cyclin B1 expression and NF-Y DNA-binding activity in 
mouse atherosclerosis. (A) Immunohistochemistry in aorta of wild-type and apoE-KO mice. The 
photomicrographs show representative examples of the indicated number of mice. Black and white 
arrowheads: internal and external elastic lamina, respectively. (B) Confocal immunofluorescence 
microscopy of aortic atheroma from fat-fed apoE-KO mice to visualize NF-YA, Mac3 (macrophages), 
and SMA (VSMCs). Arrowheads point to NF-YA/Mac3- or NF-YA/SMA-positive cells. The dashed 
line indicates the internal elastic lamina. (C) EMSA using aortic lysates from 11-month-old mice fed 
control diet and radiolabeled NF-Y consensus probe. Competition assays were carried out with 
unlabeled NF-Ycons or NF-Ymut. For supershift assays (ln.9, 10), extracts were preincubated with 
antibodies.   
 
Fig.6. Expression of NF-YA and cyclin B1 and NF-Y DNA-binding activity in human coronary 
restenosis and atherosclerosis. (A) Immunohistochemical analysis was performed in tissue obtained 
by atherectomy after a first intervention (PTCA: percutaneous transluminal coronary angioplasty; Ath: 
atherectomy). LAD: left anterior descending; RCA: right coronary artery; RCx:  Ramus circumflexus. 
NF-YA expression was graded by two independent observers (observer 1 rating/observer 2 rating) 
according to a semiquantitative scale (ND: not detected; +: weak; + +: moderate; + + +: high). The 
photomicrographs show examples of NF-YA staining in different specimens. (B) Consecutive sections 
from the same restenotic specimen illustrating regions with low and abundant NF-YA and cyclin 
B1expression. (C, D) Immunohistochemical analysis was performed in human coronary arteries with 
varying degrees of atherosclerosis according to American Heart Association criteria: early (type I and 
II), intermediate (type III), and advanced (type IV-VI) lesion. The extent of NF-YA staining was 
graded by two independent observers (observer 1 rating/observer 2 rating) according to a 
semiquantitative scale (Interm.: Intermediate; Adv.: Advanced; ND: not detected; +: weak; + +: 
moderate; + + +: extensive). The photomicrographs correspond to two magnifications of consecutive 
sections from the same specimen showing a region with abundant NF-YA and cyclin B1 expression. 
(E) EMSA performed with human arterial lysates (five patients for each condition) and radiolabeled 
NF-Y consensus probe (NF-Y binding site at -17/-13 in human CCNB1). The graph shows band 
intensities of the retarded DNA-protein complexes relative to control coronary artery (=1). (F) 
Competition assays in atherosclerotic coronary artery were carried out with a 100-fold molar excess of 
unlabeled NF-Ycons or NF-Ymut oligonucleotide. For supershift assays, lysates were preincubated 
with antibodies.   
 
Fig.7. Proposed role of NF-Y in neointimal hyperplasia. NF-Y is a downstream effector of the 
PDGF-BB-Erk1/2-Akt signaling pathway that contributes to CCNB1 expression, VSMC proliferation 
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MATERIALS AND METHODS 
 
Animal models. Care of animals was in accordance with institutional guidelines and 
regulations and animal procedures received approval from the Ethics Committee. Mice 
deficient for apolipoprotein E (apoE-KO)1 and wild-type controls (both C57BL/6J, 
Charles River, Lyon, France) were maintained on standard chow (2.8% fat; Panlab, 
Barcelona, Spain) or fed for two months an atherogenic diet containing 10.8% total fat 
and 0.75% cholesterol (S8492-E010, Ssniff, Germany).  
Balloon-angioplasty was performed in the carotid artery of Wistar rats (400 g, 14-
week-old) as previously described.2 Rats were anesthetized by intramuscular injection 
with ketamine (100 mg/kg, Ketalar, Parker Davis, Milan, Italy) and xylazine (5 mg/kg, 
Rompun, Bayer AG, Leverkusen, Germany). A 2F Fogarty balloon catheter (Edwards 
Laboratory, Santa Ana, CA) was then introduced through the external carotid artery, the 
balloon was inflated at 1.5 atmospheres and drawn towards the arteriotomy site three 
times to denude the artery.  
Endoluminal injury to the common femoral artery of 2-month-old male mice 
(C57BL/6J) was performed by 1 passage of a 0.25 mm diameter guidewire (Advanced 
Cardiovascular Systems). The guidewire was introduced and advanced through the 
femoral artery until reaching the aortic bifurcation, where a temporary ligation was 
placed to stop blood flow and allow incubation with adenovirus produced as previously 
described.3 Control mice were infected with adenovirus expressing green fluorescent 
protein (AdGFP) and experimental mice with adenovirus expressing both GFP and the 
dominant-negative nuclear factor-YA13m29 mutant (Ad(GFP+NF-YAdn))4 (a gift from R. 
Mantovani, Italy). After placing the temporary ligation, the guidewire was withdrawn, 
virus (10 µL containing 1,000 pfu/mL) was delivered intraluminally using a cannula, and 
a permanent ligation was made at the arteriotomy site. After 20 min, the distal ligation 
was removed to restore blood flow through the injured vessel segment. Mice were 
sacrificed 9 days after injury and tissue was cleaned and fixed in 4% of 
paraformaldehyde or snap-frozen for subsequent studies. Fixed tissue was paraffin-
embedded and 5-µm sections were cut through the entire injured segment. Sections 
were stained with hematoxylin-eosin and those free of thrombus were used for 
anatomical studies. An investigator blinded to treatment measured stenosis and intima 
and media area using ImageJ software (National Institutes of Health, Bethesda, MD). 
Stenosis was calculated using the following equation: 
% stenosis = 100 x [Intimal area/(Lumen area + Intimal area)].  
For each injured vessel, results represent the average from all sections analyzed. The 
procedures to assess protein expression and NF-Y DNA-binding activity are described 
below. Apoptosis was analyzed using the In Situ Cell Death Detection Kit 




Human arterial tissue. Sampling and processing of coronary artery specimens 
obtained by percutaneous directional atherectomy performed in patients with stable 
angina attributed to the presence of restenotic lesions after previous balloon angioplasty 
(9 patients) or atherectomy (1 patient) have been previously described.5 Coronary and 
internal mammary arteries were collected from patients undergoing heart transplant and 
coronary artery bypass-graft surgery, respectively (Hospital de la Santa Creu i Sant 
Pau, Barcelona, Spain). Atherosclerotic and non-atherosclerotic coronary arteries were 
from coronary artery disease (CAD) and non-CAD patients, respectively. Immediately 
after surgical excision, arteries were dissected, immersed in cell maintenance media, 
and cleaned of connective tissue and fat. Specimens for expression studies were fixed 
overnight in 4% paraformaldehyde/PBS (pH 7.4), paraffin embedded and sectioned with 
a microtome (Jung RM2055, Leica, Solms, Germany).  The presence of atherosclerotic 
lesions was evaluated by Masson’s trichrome or hematoxylin/eosin staining.6 The 
studies were approved by the ethics committees and conducted according to the 
Declaration of Helsinki. 
 
Electrophoretic mobility shift assay (EMSA). To investigate NF-Y DNA-binding 
activity, freshly-isolated arteries were snap-frozen in liquid nitrogen and stored at -80ºC 
until the preparation of protein extracts. EMSA was performed as described7 using 25 
µg of total protein from arterial lysates,8 or 5 µg of nuclear extract from vascular smooth 
muscle cells (VSMCs).9 To generate the radiolabeled NF-Y consensus probe, a double-
stranded 27-mer oligonucleotide spanning the NF-Y DNA-binding site at position -17/-13 
in the human CYCLIN B1 promoter (Forward: 5’-
CCGCAGCCGCCAATGGGAAGGGAGTGA-3’; Reverse: 5’-
TCACTCCCTTCCCATTGGCGGCTGCGG-3’; CCAAT motif underlined) was labeled 
with [32P]dATP using polynucleotide kinase (New England Biolabs, Ipswich, MA) and 
purified on a Sephadex G-50 column (GE healthcare, UK). For competition 
experiments, binding reactions contained the indicated fold-excess of unlabeled NF-Y 
consensus or NF-Y mutant, in which the CCAAT motif is disrupted (Forward: 5’-
CCGCAGCCGTTAATGGGAAGGGAGTGA-3’; Reverse: 5’-
TCACTCCCTTCCCATTAACGGCTGCGG-3’; mutations underlined). For supershift 
assays, lysates were preincubated for 25 min with 1 µg of anti-NF-YA or anti-CREBII 
(sc-10779X and sc-22800X, respectively, Santa Cruz Biotechnology, Santa Cruz, CA) 
before adding probe. Binding reactions were resolved by electrophoresis at 4ºC under 
non-denaturing conditions (5% polyacrylamide/0.5X TBE buffer). Gels were dried and 
autoradiographied and the intensity of the retarded bands was quantified with 
Metamorph and ImageQuant v5.2 (GE healthcare). 
 
Immunostaining. Human tissues were fixed as indicated above and animal tissues with 
4% paraformaldehyde/PBS. After sectioning and antigen retrieval with citrate buffer (10 
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mM, pH 6.0), specimens were blocked with 5% goat serum/phosphate buffered saline. 
Primary antibodies were anti-NF-YA (1/500-1/2000, sc-10779X), anti-cyclin B1 (1/100, 
sc-752), anti-proliferating-cell nuclear antigen (1/200, sc-7907) from Santa Cruz 
Biotechnology, anti-Ki67 (MAD-000310QD, SP6, Vitro, Madrid, Spain), anti-Mac3 
(1/500, SC-19991), phosphatase alkaline-conjugated anti-smooth muscle α-actin (SMA) 
(1/50, A5691, Sigma, St. Louis, MO) and anti-GFP (1/100, ab290, Abcam, Cambridge, 
MA). After extensive washes, sections from rat and mouse atherosclerotic vessels were 
incubated with horseradish peroxidase-conjugated goat anti-rabbit (sc-2313, Santa Cruz 
Biotechnology) or with phosphatase alkaline-conjugated anti-rat (ab7098, Abcam) 
secondary antibodies and sections from human specimens or mouse femoral arteries 
with biotinylated anti-rabbit antibodies (atherosclerotic samples: BA-1000, Vector Labs., 
Burlingame, CA; murine and human restenotic samples: 111-066-003, Jackson 
ImmunoResearch, Suffolk, UK). Immunocomplexes conjugated to horseradish 
peroxidase were detected with Vectastain Elite ABC reagent (PK6100, Vector) and DAB 
substrate (AbD Serotec, Dusseldorf, Germany). Immunocomplexes conjugated to 
phosphatase alkaline were detected with Warp Red Chromogen Kit (WR806, Biocare 
Medical, Concord, CA).  
Immunostaining in rodent histological sections was quantified by computer-assisted 
morphometric analysis using ImageJ software (National Institutes of Health) and 
immunoreactive area is presented as a percentage of the total neointimal area. The 
extent of immunostaining in human histological sections was graded by two 
independent observers according to a semiquantitative scale (ND: not detected; +: 
weak; ++: moderate; +++: high). 
Primary antibodies for confocal immunofluorescence were anti-NF-YA (1/2000, sc-
10779X), anti-Mac3 (1/500, SC-19991) and anti-cyclin-B1 (1/100, sc-245) from Santa 
Cruz Biotechnology, and Cy3-conjugated anti-SMA (1/1000, C6198, Sigma). Secondary 
antibodies were Alexa Fluor 488- or 555-conjugated goat anti-rabbit, Alexa Fluor 488-
conjugated goat anti-mouse, and Alexa Fluor 633-conjugated goat anti-rat (A11034, 
A21429, A11029 and A21094, respectively, Invitrogen, Breda, The Netherlands). For 
endothelial cell staining, tissue was incubated with biotinylated-isolectin B4 (1/20, 
L2140, Sigma) in PBS containing 1% Triton X-100, 0.1 mM CaCl2, 0.1 mM MgCl2 and 
0.1 mM MnCl2, followed by incubation with Alexa Fluor 647-conjugated streptatividin 
(S21374, Invitrogen).  Images were acquired with a laser microscope (TCS/SP2, Leica, 
Wetzlar, Germany, or A1R, Nikon, Melville, NY) and image colocalization was evaluated 
with MetaMorph (Danaher Corporate Office, Downingtown, PA). 
 
Cell culture and adenoviral infection. Cells were maintained at 37ºC in 5% CO2. Rat 
VSMCs were obtained from thoracic aortas of Wistar-Kyoto rats by collagenase 
digestion.10 E19P cells (gift from C. Shanahan, University of Cambridge, UK) were 
obtained from explant cultures of embryonic day 19 aorta from Fischer rats. Cells were 
cultured in DMEM medium (Invitrogen) supplemented with heat-inactivated fetal bovine 
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serum (FBS, Sigma) (10% and 20% FBS for E19P and primary rat VSMCs, 
respectively) and 1% penicillin/streptomycin (Gibco, Invitrogen). For isolation of mouse 
aortic endothelial cells (mAECs), segments of abdominal and thoracic aortas were 
dissected and processed as previously described.11 Explants were not disturbed during 
the first days. After outgrowth of adherent cells, a positive selection was performed 
using anti-ICAM-2 antibody (553326, clone 3C4, BD Biosciences), which yielded a 
population of endothelial cells with a >95% purity. mAECs were cultured in DMEM:F12, 
1:1 Mixture 12-719F (BE12-719F, Lonza, Basel, Switzerland) supplemented with 10% 
FBS, heparin (0.1 mg/ml, H3393, Sigma), Endothelial Cell Growth Supplement (ECGF, 
50 μg/ml, 354006, Becton Dickinson, Franklin Lakes, NJ), 1% penicillin/streptomycin 
(Gibco, Invitrogen), glutamine, 10 mM Hepes and fungizone. VSMCs from human 
coronary arteries were obtained as previously described12 and were maintained with 
20% FBS/2% human serum in M199 medium (Gibco, Invitrogen).  
Cells were infected for 6 hours with AdGFP or Ad(GFP+NF-YAdn) (see above) at a 
multiplicity of infection of 200 in serum-free DMEM supplemented with 1% 
penicillin/streptomycin (VSMCs) and at a multiplicity of infection of 500 in serum-free 
DMEM:F12 supplemented with 1% penicillin/streptomycin (mAECs). After infection, 
cells were treated as follows: primary rat VSMCs were maintained with 20% FBS in 
DMEM, E19P were maintained for 24 hours with DMEM supplemented with mitogen-
free insulin-transferrin-selenium media (Invitrogen), human VSMCs were maintained for 
24 hours with 0.2% FBS in M199, and mAECs were maintained for 24 hours with 
DMEM:F12 supplemented with 10% FBS, 0.1 mg/mL heparin and 50 μg/ml of ECGF. 
For platelet-derived growth factor-BB (PDGF-BB) stimulation experiments, E19P cells 
were starved during 72 hours with mitogen-free insulin-transferrin-selenium/DMEM, and 
human VSMCs were starved during 48 hours with 0.2% FBS/M199. To induce cell cycle 
reentry, serum-starved E19P cells and human VSMCs were stimulated with 10 ng/mL of 
rat PDGF-BB (Sigma) and 20 ng/mL of human PDGF-BB (R&D Systems, Minneapolis), 
respectively, and then harvested at different times for chromatin immunoprecipitation 
(ChIP), quantitative real-time PCR (qPCR) or proliferation assays (see below). When 
indicated, cells were incubated with the following inhibitors during the last hour of serum 
starvation and throughout the period of PDGF-BB stimulation: 5 µM U0126 (MEK 
inhibitor, Promega, Madison, Wisconsin), 5 µM AKT inhibitor X (Calbiochem, EMD 
Chemicals, Inc., Gibbstown, NJ), or 10 µM SB203580 (p38-MAPK inhibitor, 
Calbiochem, EMD Chemicals).   
 
Chromatin immunoprecipitation (ChIP) assay. To quantify the in vivo recruitment of 
NF-Y to the CCNB1 promoter, VSMCs (8x106 cells) were fixed by supplementing the 
medium with formaldehyde (1% final concentration, 10 minutes). Cells were extensively 
washed with ice-cold phosphate-buffered saline and then lysed for 5 minutes in L1 
buffer (50 mM Tris, pH 8.0, 2 mM EDTA, 0.1% NP-40, 10% glycerol) supplemented with 
protease inhibitors (Complete Protease Inhibitor Cocktail, Roche Applied Science, 
Indianapolis, IN). Nuclei were collected at 3,000 rpm in a microfuge and resuspended in 
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L2 buffer (50 mM Tris, pH 8.0, 1% SDS, 5 mM EDTA). Chromatin was sheared by 
sonication using a Bioruptor (Diagenode, Liege, Belgium), centrifuged to pellet debris, 
and diluted 10 times in 0.5% NP-40/0.2 M NaCl/0.5 mM EDTA/50 mM Tris, pH 8.0. 
Immunoprecipitation with 3 μg of polyclonal anti-NF-YA or isotype IgG control antibody 
(sc-10779X and sc-2027 respectively, Santa Cruz Biotechnology) was performed 
overnight at 4°C. Immune complexes were collected with salmon sperm DNA-saturated 
protein A, washed three times with high-salt washing buffer (20 mM Tris, pH 8.0, 0.1% 
SDS, 1% NP-40, 2 mM EDTA, 500 mM NaCl), two times with a 0.5 M LiCl buffer, and 
three times with low-salt TE buffer (5 minutes each wash). Immune complexes were 
extracted in TE containing 2% SDS and protein and DNA cross-links were reverted by 
heating at 65°C for 6 hours. DNA was extracted using QIAquick PCR purification kit 
(Qiagen, Valencia, CA). Approximately 1/20 of the immunoprecipitated DNA was used 
in each PCR reaction. The following primers were designed using the Autoprime 
software (www.autoprime.de) (sequence from 5’ to 3’):  
 
Rat CCNB1 (Melting temperature: 67ºC):  
Forward: GCTCTGCCATTTATCATCACT 
Reverse: TGACTGCCAAGCAAGGAAGC 
Human CCNB1 (Melting temperature: 72ºC):  
Forward: CGATCGCCCTGGAAACGCATT 
Reverse: CCAGCAGAAACCAACAGCCGT 
Each experimental condition was analyzed in triplicate. Results were normalized using 
the isotype IgG control and the  cycle threshold method and are expressed relative to 
control group (defined as 1). 
 
Quantitative PCR (qPCR). Total RNA was isolated from VSMCs using Qiazol (Qiagen). 
RNA was quantified by spectrophotometry at 260nm and its purity was assessed by the 
A260nm/A280nm ratio. RNA integrity was verified by separation on ethidium bromide-
stained 1% agarose gels. RNA (0.5 to 2µg) from VSMCs was retrotranscribed using the 
High Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Carlsbad, CA). 
qPCR was performed using SYBR Green PCR Master mix (Applied Biosystems) and 
the following primers (sequence from 5’ to 3’):  
 
Rat NF-YA (Melting temperature: 60 oC):  
Forward: GGAGCCTCTGATTGGGTTTC 




Rat CCNB1 (Melting temperature: 58 oC):  
Forward: ATGCAGCACCTGGCTAAGAAC 
Reverse: CATGCTTAGATGTTGCATACTTGT  
Rat 18S (Melting temperature: 60 oC):  
Forward: CGGCTACCACATCCAAGGAA 
Reverse: AGCTGGAATTACCGCGGC  
Human CCNB1 (Melting temperature: 60 oC):  
Forward: AGCTGCTGCCTGGTGAAGAG 
Reverse: GCCATGTTGATCTTCGCCTTA  
Human HPRT1 (Melting temperature: 60 oC):  
Forward: AATTGACACTGGCAAAACAATGC 
Reverse: ATGGTCAAGGTCGCAAGCTT  
 
qPCR results were normalized using the housekeeping genes 18S (rat studies) and 
HPRT1 (human studies) and the comparative Ct method. 
 
Proliferation assays. For the experiments of Fig.3C, primary rat VSMCs 
asynchronously growing in the presence of 20% FBS were infected with Ad-GFP or Ad-
GFP-NF-YAdn (see above) and incubated with 50 µM 5-bromo-2'-deoxyuridine (BrdU) 
(Sigma) for 16 hours. The percentage of BrdU-immunoreactive cells was determined in 
infected cells (GFP-positive). For the rest of proliferation assays, cells were incubated 
with 50 µM BrdU during the last 2 hours (Fig.2A, B) or 24 hours (Fig.2C, 3D) of PDGF-
BB stimulation. Cells were fixed for 30 minutes with 4% paraformaldehyde/PBS, 
permeabilized with 0.5% Triton X-100/2 M HCl, washed extensively with sodium borate 
buffer (pH 8.5), and incubated with a rabbit polyclonal anti-GFP antibody (1/500, A6455, 
Invitrogen). Next, cells were incubated with mouse monoclonal anti-BrdU antibody 
(1/200, 11-286-c100, clone MoBu-1, Exbio, Vestec, Czech Republic) followed by a 
biotinylated goat anti-mouse secondary antibody (BA-9200, Vector Labs, Burlingame, 
CA), Cy3-conjugated streptavidin (016-160-084, Jackson ImmunoResearch, Suffolk, 
UK) and Alexa Fluor 488-conjugated goat anti-rabbit secondary antibody (A11034, 
Molecular Probes, Invitrogen). Nuclei were stained with Hoechst (1/1000, Sigma) for 
total cell count, and coverslips were mounted with slow-fade gold antifade reagent 
(Invitrogen) and analyzed in an Axiovert 200M fluorescent microscope (Zeiss, 
Germany). For experiments of Supplemental Fig. IB, mAECs were starved in 
DMEM:F12 for 48 hours. To induced cell cycle reentry, mAECs were stimulated with 
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DMEM:F12 supplemented with 10% FBS, 0.1 mg/mL heparin and 50 μg/ml ECGF for 
24 hours. mAECs were incubated with 50 µM BrdU during the last 24 hours. The 
percentage of BrdU-immunoreactive cells was determined in infected cells (GFP-
positive) as BrdU-APC-positive cells using the BrdU flow kit (557892, Becton Dickinson 
Pharmigen).  
 
In vitro apoptosis assays. VSMCs and mAECs were infected with adenoviral vectors 
as described above. Cells were grown in the presence of 10% FBS, 0.1 mg/mL heparin 
and 50 μg/ml ECGF (mAECs, Supplemental Fig. IB) or 20% FBS (rat VSMCs, 
Supplemental Fig. IIIA) and apoptosis was analyzed by supravital incubation with 
0.003% propidium iodide as described.13  
 
Western blot. Cytoplasmic and nuclear lysates were prepared as described. 9 Lysates 
(50 µg protein) were separated by SDS-PAGE and transferred onto Immobilon-P 
membranes (Millipore Corporation, Billerica, MA). Membranes were blocked in 4% dry 
milk and incubated with primary antibodies (anti-NF-YA, 1/1000, 200-401-100, 
Rockland, Gilbertsville, Pensilvania; anti-lamin A/C, 1/300, sc-6215, Santa Cruz 
Biotechnology). Secondary horseradish peroxidase-coupled anti-isotype-specific 
antibodies (Santa Cruz Biotechnology) were used for detection with enhanced 
chemiluminescence reagent (ECL Plus; GE Healthcare, UK). 
 
Statistical analysis. Results are expressed as mean±SEM and analyzed using SPSS 
(SPSS Inc., Chicago, IL) and GraphPad-Prism (GraphPad Software, LaJolla, CA). 
Statistical significance was considered when p<0.05, as determined by paired 2-sided 
Student’s t test (2 experimental groups) and one-way or two-way ANOVA followed by 
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